Advertisement

Methotrexate Tablets

[17 May 2013]

Products Affected - Description

Methotrexate tablets, Major
2.5 mg, 100 count (NDC 00904-6012-60)-discontinued

Methotrexate tablets, Mylan Pharmaceuticals
2.5 mg, 100 count (NDC 00378-0014-01)
 
Methotrexate tablets, Roxane
2.5 mg, 36 count (NDC 00054-4550-15)
2.5 mg, 100 count (NDC 00054-4550-25)
2.5 mg, unit dose, 100 count (NDC 00054-8550-25)

Trexall tablets, Teva
2.5 mg, 36 count (NDC 00555-0572-35)
2.5 mg, 100 count (NDC 00555-0572-02)

Reason for the Shortage

  • Major discontinued methotrexate tablets in 2013.
  • Roxane and Teva could not provide a reason for the shortage.

Available Products

Methotrexate tablets, Dava Pharmaceuticals
2.5 mg, 36 count (NDC 67253-0320-36)
2.5 mg, 100 count (NDC 67253-0320-10)
 
Rheumatrex Dose Pack, Dava Pharmaceuticals
2.5 mg, 8 count (NDC 67253-0580-42)
2.5 mg, 12 count (NDC 67253-0580-43)
2.5 mg, 16 count (NDC 67253-0580-44)
2.5 mg, 20 count (NDC 67253-0580-45)
2.5 mg, 24 count (NDC 67253-0580-46)
 
Methotrexate tablets, Mylan Institutional, Inc
2.5 mg, unit dose, 20 count (NDC 51079-0670-05)

Methotrexate tablets, Mylan Pharmaceuticals
2.5 mg, 5000 count (NDC 00378-0014-50)
 
Trexall tablets, Teva
5 mg, 30 count (NDC 51285-0366-01)
7.5 mg, 30 count (NDC 51285-0367-01)
10 mg, 30 count (NDC 51285-0368-01)
15 mg, 30 count (NDC 51285-0369-01)

Estimated Resupply Dates

  • Mylan has methotrexate 2.5 mg in 100 count on back order and the company estimates a release date in mid- to late-May 2013.
  • Roxane has methotrexate 2.5 mg tablets in 36 count and 100 count on intermittent back order and the company is releasing product as it becomes available. The 2.5 mg 100 count (NDC 00054-8550-25) is on back order and the company estimates a release date late-May 2013.
  • Teva has methotrexate 2.5 mg tablets in 36 count and 100 count on back order with an estimated release date in late-June 2013.


Related Shortages

Updated

May 17, 2013; April 5, 2013; February 14, 2013; December 21, 2012; December 7, 2012; November 7, 2012; October 26, 2012; October 3, 2012; September 18, 2012. University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity

Get the latest updates on ASHP's advocacy activity on drug shortages.



In Cooperation With
University of Utah & Novation
Advertisement